Abstract:Oroxylin A directly targets transketolase (TKT) to suppress the non‐oxidative pentose phosphate pathway and activate p53 signalling, leading to growth inhibition of hepatocellular carcinoma (HCC) cells, tumours, and patient‐derived tumour organoids. This will facilitate the development of small‐molecule inhibitors of TKT and novel therapeutics for HCC. Background Transketolase (TKT), a key rate‐limiting enzyme in the non‐oxidative branch of the pentose phosphate pathway (PPP), provides more than 85% of the ribose required for de novo nucleotide biosynthesis and promotes the development of hepatocellular carcinoma (HCC). Pharmacologic inhibition of TKT could impede HCC development and enhance treatment efficacy. However, no safe and effective TKT inhibitor has been approved. Methods An online two‐dimensional TKT protein immobilised biochromatographic system was established for high‐throughput screening of TKT ligands. Oroxylin A was found to specifically bind TKT. Drug affinity responsive target stability, cellular thermal shift assay, surface plasmon resonance, molecular docking, competitive displacement assay, and site mutation were performed to identify the binding of oroxylin A with TKT. Antitumour effects of oroxylin A were evaluated in vitro, in human xenograft mice, diethylnitrosamine (DEN)‐induced HCC mice, and patient‐derived organoids (PDOs). Metabolomic analysis was applied to detect the enzyme activity. Transcriptome profiling was conducted to illustrate the anti‐HCC mechanism of oroxylin A. TKT knocking‐down HCC cell lines and PDOs were established to evaluate the role of TKT in oroxylin A‐induced HCC suppression. Results By targeting TKT, oroxylin A stabilised the protein to proteases and temperature extremes, decreased its activity and expression, resulted in accumulation of non‐oxidative PPP substrates, and activated p53 signalling. In addition, oroxylin A suppressed cell proliferation, induced apoptosis and cell‐cycle arrest, and inhibited the growth of human xenograft tumours and DEN‐induced HCC in mice. Crucially, TKT depletion exerted identical effects to oroxylin A, and the promising inhibitor also exhibited excellent therapeutic efficacy against clinically relevant HCC PDOs. Conclusions These results uncover a unique role for oroxylin A in TKT inhibition, which directly targets TKT and suppresses the non‐oxidative PPP. Our findings will facilitate the development of small‐molecule inhibitors of TKT and novel therapeutics for HCC.

ONTD Induces Growth Arrest and Apoptosis of Human Hepatoma Bel-7402 Cells Though a Peroxisome Proliferator-Activated Receptor Γ-Dependent Pathway.

ONTD Induces Apoptosis of Human Hepatoma Bel-7402 Cells Via a MAPK-dependent Mitochondrial Pathway and the Depletion of Intracellular Glutathione.

Natural product pectolinarigenin inhibits proliferation, induces apoptosis, and causes G2/M phase arrest of HCC via PI3K/AKT/mTOR/ERK signaling pathway.

The Inhibitory Effect of 3Β-Hydroxy-12-oleanen-27-oic Acid on Growth and Motility of Human Hepatoma HepG2 Cells Through JNK and Akt Signaling Pathway

Osu-03012, A Novel Celecoxib Derivative, Induces A Unique Autophagy-Like Cell Death In Human Hepatocellular Carcinoma Cells

Osu-03012, A Novel Celecoxib Derivative, Induces Reactive Oxygen Species-Related Autophagy In Hepatocellular Carcinoma

The novel glycyrrhetinic acid–tetramethylpyrazine conjugate TOGA induces anti-hepatocarcinogenesis by inhibiting the effects of tumor-associated macrophages on tumor cells

Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9

ONX0912, a Selective Oral Proteasome Inhibitor, Triggering Mitochondrial Apoptosis and Mitophagy in Liver Cancer.

(2E)-1-(2,4,6-trimethoxyphenyl)-3-(3-nitrophenyl)-2-propen-1-one Promotes Apoptosis By Regulating ERK/MAPK Pathway In Hepatocellular Carcinoma Cells

A New Oridonin Analog Suppresses Triple-Negative Breast Cancer Cells and Tumor Growth Via the Induction of Death Receptor 5

ONC206 targeting ClpP induces mitochondrial dysfunction and protective autophagy in hepatocellular carcinoma cells

Novel transketolase inhibitor oroxylin A suppresses the non‐oxidative pentose phosphate pathway and hepatocellular carcinoma tumour growth in mice and patient‐derived organoids

Giganteaside D Induces ROS-mediated Apoptosis in Human Hepatocellular Carcinoma Cells Through the MAPK Pathway.

Apoptosis Induction of ZBB-006, a Novel Synthetic Diterpenoid, in the Human Hepatocellular Carcinoma Cell Line HepG2 in Vitro and in Vivo.

NOAD, a Novel Nitric Oxide Donor, Induces G2/M Phase Arrest and Apoptosis in Human Hepatocellular Carcinoma Bel-7402 Cells

OAMDP, a novel podophyllotoxin derivative, induces apoptosis, cell cycle arrest and autophagy in hepatoma HepG2 cells.

Apoptosis induced by 1,3,6,7-tetrahydroxyxanthone in Hepatocellular carcinoma and proteomic analysis

Oridonin Derivatives As Potential Anticancer Drug Candidates Triggering Apoptosis Through Mitochondrial Pathway in the Liver Cancer Cells

Pentoxifylline Induces Apoptosis of HepG2 Cells by Reducing Reactive Oxygen Species Production and Activating the MAPK Signaling.

Activation of the unfolded protein response contributed to the selective cytotoxicity of oroxylin A in human hepatocellular carcinoma HepG2 cells.